AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17538805
Drug: 3% terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% terbinafine emulsion gel
Trial: 17538805
Drug: 1% terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% terbinafine emulsion gel
Trial: 9891541
Drug: Induction platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction platinum based chemotherapy
Trial: 4827463
Drug: Diazepam (Valium),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (Valium), 20 mg daily for at least 5 consecutive days
Trial: 27543211
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) alone
Trial: 27543211
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (TCS) + dilute bleach bath
Trial: 15068851
Drug: Long-term HAART
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term HAART treatment
Trial: 15068851
Drug: Single structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single structured therapy interruption (STI)
Trial: 11176590
Drug: Ofloxacin (Floxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (Floxin otic)
Trial: 11176590
Drug: Oral amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanate (Augmentin)
Trial: 7916278
Drug: Inactivated MUKC
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated MUKC vaccine (3 doses)
Trial: 16301238
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg ropivacaine (7.5 mg/mL) alone (control group)
Trial: 16301238
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg ropivacaine combined with 75 mug clonidine (clonidine group)
Trial: 31204605
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT; n= 21)
Trial: 31932513
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 0.8 mg with enalapril 10 mg
Trial: 29273594
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg alone
Trial: 26550817
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronic acid (HA) + oral viscosupplementation (IA)
Trial: 26550817
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronic acid (HA) only
Trial: 10440419
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg
Trial: 14738561
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) therapy
Trial: 8432223
Drug: Acarbose 25
RxNorm normalized name: acarbose 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 25 mg powdered, 3 times a day with meals for 3 months
Trial: 3829440
Drug: S-carboxymethylcysteine (2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-carboxymethylcysteine (2.25 g per day for 7 days)
Trial: 31791364
Drug: Exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise plus Nutrition (Combination)
Trial: 31791364
Drug: Exercise, Nutrition,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise, Nutrition, and Combination groups
Trial: 30320657
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation (2 drops placed 15 to 20 cm away from the pillow, 30 minutes before bed for 1 week)
Trial: 31567306
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation
Trial: 29325238
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication
Trial: 17215186
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 supplementation (500 microg)
Trial: 8317404
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac tromethamine (KT)
Trial: 30033064
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg) and 2 injections of normal saline (group B)
Trial: 30033064
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg) and 2 injections of low-dose (10 mg) dexamethasone (group C)
Trial: 23228033
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with clinical‐radiological severity mismatch (NIHSS score ≥ 10 and infarct volume <20 cc)
Trial: 23228033
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with NIHSS score ≥ 10 and infarct volume ≥ 20 cc
Trial: 21942462
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) users
Trial: 21942462
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) users (low adherence)
Trial: 21942462
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) users (medium adherence)
Trial: 21942462
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI) users (high adherence)
Trial: 30449719
Drug: Bevacizumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 7.5 mg/kg every 3 weeks for 6 cycles followed by single-agent bevacizumab for 12 further cycles (total duration 12 months)
Trial: 25164872
Drug: Exogenous surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous surfactant (200 mg/kg poractant alfa) via the Hobart method
Trial: 18922386
Drug: Camu-camu juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camu-camu juice (70 ml daily for 7 days, 1050 mg of vitamin C)
Trial: 9272342
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccines
Trial: 10732318
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg
Trial: 25858239
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment following intravenous tissue-type plasminogen activator
Trial: 26012639
Drug: Intravenous tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue-type plasminogen activator alone
Trial: 19590458
Drug: CEE/MPA (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Trial: 15497663
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg tablets
Trial: 15497663
Drug: Azithromycin 200
RxNorm normalized name: AZITHROMYCIN 200MG/5ML SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 200 mg/5 mL suspension
Trial: 9331518
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg once daily for 10 days
Trial: 9331518
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg once daily for 10 days + Selegiline 10 mg once daily for 4 days
Trial: 2831262
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NS) 1% solution, 0.13 ml nasal spray, administered at least twice daily
Trial: 10371003
Drug: Interocclusal appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interocclusal appliance therapy
Trial: 8592096
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of epinephrine at 12.5, 25, and 50 ng/(kg x min) for 1 hour each
Trial: 8470415
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution
Trial: 10149510
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass circuits
Trial: 6362341
Drug: 50-150 mg
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-150 mg Slow Apresoline once daily
Trial: 26831302
Drug: Liraglutide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, and 1.8 mg for 3 days)
Trial: 15808246
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Trial: 15808246
Drug: Sub-Tenon's capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon's capsule injection of 5 ml of a 50:50 mixture of 4% lidocaine and 0.75% bupivacaine
Trial: 1313068
Drug: Dexamethasone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.6 mg/kg intravenously as a loading dose followed by 0.2 mg/kg every 6 h for 5 days
Trial: 18155988
Drug: Higher-energy-density entrée
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-energy-density entrée (2.0 kcal/g)
Trial: 1364273
Drug: Oxatomide (Tinset)
RxNorm normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (Tinset) tablets
Trial: 27075863
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg and 80 mg
Trial: 17914201
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% cyclosporine drops
Trial: 15384858
Drug: Urokinase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase therapy
Trial: 2688602
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg
Trial: 3555588
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg (C50)
Trial: 3555588
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg (HCTZ 25)
Trial: 3555588
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg (C50/HCTZ 25)
Trial: 31634877
Drug: Medication Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Therapy Management program (MTM)
Trial: 19019476
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 microg twice-daily
Trial: 17955656
Drug: Lianbai liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lianbai liquid (treatment group)
Trial: 15763649
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) comprising vincristine, etoposide, carboplatin, and cyclophosphamide followed by craniospinal RT 35 Gy/21 fractions with a posterior fossa boost 20 Gy/12 fractions.
Trial: 15763649
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) followed by craniospinal RT with a metastatic boost.
Trial: 15763649
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) prior to RT.
Trial: 12197849
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (81 mg daily for 7 days)
Trial: 9860148
Drug: M2 (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2 (reference mefloquine tablet)
Trial: 1263629
Drug: Nurse practitioner
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse practitioner with more frequent and longer patient visits, ordered more medications, less physician consultation.
Trial: 21291323
Drug: 2.0 million
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 million international units of IL-2 subcutaneously daily during the final 2 weeks of treatment interruption and the first week of treatment reinitiation (Arm A)
Trial: 17268388
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BT-A) injections (3 successive doses to the calf muscle bilaterally at intervals of 3 to 4 months)
Trial: 30511430
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste with amoxicillin (TAPa)
Trial: 30511430
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste with cefaclor (TAPc)
Trial: 30511430
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste with doxycycline (TAPd)
Trial: 30511430
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic paste with minocycline (TAPm)
Trial: 26076302
Drug: Water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water spray
Trial: 16778714
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg after pretreatment with clarithromycin 800 mg/d
Trial: 16778714
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg after pretreatment with fluvoxamine 50 mg/d
Trial: 3379143
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 mg intramuscularly or 1.0 mg orally)
Trial: 26554316
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in an open general psychiatric ward
Trial: 22983284
Drug: Glycyrrhizin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (75 mg three times daily for 6 days)
Trial: 19705923
Drug: meloxicam 30
RxNorm normalized name: meloxicam 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 30 mg with cholestyramine
Trial: 8771595
Drug: loprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loprazolam (1 mg)
Trial: 1607582
Drug: Encainide, flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide, flecainide or moricizine (upwardly titrated doses)
Trial: 21641362
Drug: Adiponectin greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin greater than the median (4,477 ng/mL)
Trial: 9143000
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) 10 micrograms
Trial: 9143000
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone (ACTH) 1 microgram
Trial: 18266664
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of antipsychotics
Trial: 25416723
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg in 11/15 patients)
Trial: 25416723
Drug: High-dose glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glucocorticoids (n=11) or physiological replacement doses (n=4)
Trial: 31485774
Drug: Concentrations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrations of two terpenoid compounds (β‐caryophyllene, α‐humulene)
Trial: 29562041
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management model with individual training on hypertension causes, risk factors, significance, unwanted side effects, medication treatment, and lifestyle changes.
Trial: 24044709
Drug: 810-nm subthreshold
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 810-nm subthreshold diode micropulse (SDM) laser treatment
Trial: 11514368
Drug: High-dose gamma-irradiation
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gamma-irradiation (18 Gy at 2 mm from the source)
Trial: 9024023
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV administered at the end of surgery
Trial: 9024023
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV administered before induction of anesthesia
Trial: 9024023
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 5 mL) administered prior to induction and at the end of surgery
Trial: 25376140
Drug: Arthrocentesis (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis (AC) with corticosteroids (dexamethasone 8 mg)
Trial: 7559887
Drug: GHRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH plus atenolol (1 mg/kg)
Trial: 1641600
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg b.i.d.
Trial: 22773670
Drug: Conditioned with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioned with Prompt L‐pop self‐etching primer (Group IV)
Trial: 21332825
Drug: Propiverine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine (20 mg once daily)
Trial: 3918688
Drug: Omeprazole 30
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 30 mg daily
Trial: 19861577
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline CTC (three or more CTC per 7.5 ml of blood)
Trial: 19861577
Drug: High CTC
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CTC at 1-2 weeks after the start of treatment
Trial: 20384600
Drug: Venlafaxine 150
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 150 mg
Trial: 27859267
Drug: Buspirone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 20 mg
Trial: 8862936
Drug: Meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 15 mg i.v. on day 1 followed by 7 days oral treatment with one 15 mg tablet daily
Trial: 8862936
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg i.m. on day 1 followed by 7 days treatment with one 100 mg slow release tablet daily
Trial: 1442760
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel patch (10% lidocaine base with 3% glycyrrhetinic acid) applied for 60 minutes
Trial: 1442760
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel patch
Trial: 3899624
Drug: Flunarizine at
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine at doses of 0, 10, 15, 20, and 25 mg daily
Trial: 20051836
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) (5,000 U per catheter line)
Trial: 10193952
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2 on Day 1) and Etoposide (100 mg/m2 on Days 1, 3, and 5 or Days 4, 6, and 8 every 3 weeks)
Trial: 229146
Drug: Flurazepam hydrochloride
RxNorm normalized name: Flurazepam Hydrochloride
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurazepam hydrochloride (15 mg)